Barriers to treatment of infectious and other somatic comorbidity in drug users
Authors:
V. Mravčík 1,2,3; J. Kožený 2,4; V. Nečas 5; L. Tišanská 2,4
Authors‘ workplace:
Národní monitorovací středisko pro drogy a závislosti, Praha
1; Národní ústav duševního zdraví, Klecany
2; Klinika adiktologie, 1. lékařská fakulta, Univerzita Karlova a Všeobecná fakultní nemocnice v Praze
3; 3. lékařská fakulta, Univerzita Karlova, Praha
4; Fakulta sociálních věd, Univerzita Karlova, Praha
5
Published in:
Epidemiol. Mikrobiol. Imunol. 69, 2020, č. 2, s. 73-80
Category:
Original Papers
Overview
Background: Intensive use of illicit drugs in general and drug injecting in particular are associated with higher somatic co-morbidity, especially of infectious aetiology. The treatment participation of drug users is complicated by a number of barriers.
Material and methods: At the end of 2013, a cross-sectional questionnaire study was conducted on a non-random sample of 240 drug users (188 men and 52 women) recruited in low-threshold drug services in Prague based on their willingness to participate in the study. Drug injecting sometimes in their lifetime was reported by 237 respondents (98.8%), injecting drug use in the last 12 months by 232 (96.7%), and injecting drug use in the last 30 days by 228 (95.0%). The questionnaire included 38 of the 59 original items from the Barriers to Treatment Inventory (BTI). Factor analysis of these items was performed. In addition to the questionnaire survey, two focus groups with a total of 14 clients were carried out.
Results: The factor analysis resulted in a 5-factor model that was fed with 23 BTI items. The factors identified can be interpreted as: (1) difficulty entering treatment due to additional responsibilities (e.g. children, family, work, etc.), (2) previous poor treatment experience, fear and concerns about the treatment or negative attitudes of staff, (3) financial difficulties and formal barriers (health insurance debts, problems with the law, etc.), (4) concerns that entering treatment will be too complicated and difficult, (5) distrust of the treatment's ability to improve the client's life situation. The results of the focus groups have shown that drug users face stigmatization and discrimination in healthcare facilities.
Conclusion: The access to treatment of infectious and other somatic co-morbidity in drug users is complicated by a number of barriers, which largely arise from the lifestyle and socio-economic situation associated with drug use and from negative experiences with the attitude of medical staff. Healthcare professionals should actively identify and respond to barriers to care among drug users by taking appropriate measures in the context of a multidisciplinary approach and cooperation.
Keywords:
somatic comorbidity – infectious diseases – drug use – injecting drug use – barriers to care
Sources
1. Gossop M. Treating drug misuse problems: evidence of effectiveness. London: National treatment Agency for Substance Misuse; 2006, 2009.
2. Schulte B, Thane K, Rehm J, Uchtenhagen A, Stöver H, Degkwitz P, et al. Review of the efficacy of drug treatment interventions in Europe: European Commission and Centre for interdisciplinary addiction research (ZIS) of the Hamburg University, 2008.
3. Hunt N, Ashton M, Lenton S, Mitcheson L, Nelles B, Stimson G. A review of the evidence-base for harm reduction approaches to drug use Forward Thinking On Drugs 2003 [cited 2020-05-09]. Dostupné na https://neilhunt.org/pdf/2003-evidence-base-for-hr-hunt-et-al.pdf
4. Mravčík V, Florián Z, Nečas V, Štolfa J. Infekční a další somatická komorbidita problémových uživatelů drog – výsledky průřezové studie s lékařským vyšetřením. Epidemiologie, Mikrobiologie, Imunologie, 2016;1(65):56–62.
5. Mravčík V, Mladá K, Drbohlavová B. Infectious and Other Somatic Comorbidity in People who Inject Drugs – Results of a Cross-sectional Survey. Adiktologie, 2018;18 (3–4):141–150.
6. Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? Journal of health and social behavior, 1995;36(1):1–10.
7. Allen K, Dixon M. Psychometric assessment of the Allen Barriers to Treatment Instrument. The International journal of the addictions, 1994;29(5):545–563.
8. Allen K. Development of an instrument to identify barriers to treatment for addicted women, from their perspective. The International journal of the addictions, 1994;29(4):429–444.
9. Rapp RC, Xu J, Carr CA, Lane DT, Wang J, Carlson R. Treatment barriers identified by substance abusers assessed at a centralized intake unit. J Subst Abuse Treat., 2006;30(3):227–235.
10. Xu J, Wang J, Rapp RC, Carlson RG. The Multidimensional Structure of Internal Barriers to Substance Abuse Treatment and Its Invariance Across Gender, Ethnicity, and Age. J Drug Issues, 2007;37(2):321–340.
11. Xu J, Rapp RC, Wang J, Carlson RG. The multidimensional structure of external barriers to substance abuse treatment and its invariance across gender, ethnicity, and age. Substance abuse: official publication of the Association for Medical Education and Research in Substance Abuse, 2008;29(1):43–54.
12. Grebely J, Raffa JD, Lai C, Krajden M, Kerr T, Fischer B, et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat., 2009;16(5):352–358.
13. Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. Harm Reduct J., 2013;10:7.
14. Mravcik V, Strada L, Stolfa J, Bencko V, Groshkova T, Reimer J, et al. Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review. Patient Prefer Adherence, 2013;7:1067–1075.
15. European Association for The Study of The Liver. "EASL recommendations on treatment of hepatitis C 2018." Journal of Hepatology 2018; 69(2):461–511.
16. Hajarizadeh B, Cunningham EB, Reid H, Law M, Dore GJ, Grebely J. Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. The lancet Gastroenterology & hepatology, 2018.
17. Galský J, Husa P, Hejda V, Kümpel P, Němeček V, Plíšek S, et al. Standardní diagnostický a terapeutický postup chronické infekce virem hepatitidy C (HCV). Klinická mikrobiologie a infekční lékařství, 2012;18(3):75 –89.
18. Muthén LK, Muthén BO. Mplus User’s Guide. Eighth Edition. Los Angeles, CA: Muthén & Muthén, 1998–2017.
19. Miovský M. Kvalitativní přístup a metody v psychologickém výzkumu: Grada Publishing, a.s., 2006.
20. Tyrlík M, Bém P, Zuda T, Power R. Zhodnocení drogové situace v ČR. Aktualizovaná verze zprávy „Rapid Assessment of the Drug Use Situation in the Czech Republic“, 1996.
21. Minařík J, Zahradník M. Zhodnocení drogové situace v Pardubickém kraji (Rapid assessment), 2003.
22. Miovský M, Zábranský T, Bullington BB. Přehled výsledků substudie provedené s uživateli nelegálních psychoaktivních látek a pracovníky zdravotnických zařízení a významnými poskytovateli služeb uživatelům nelegálních drog. Adiktologie, 2001;1(supplementum):45–79.
23. Miovská L, Miovský M, Gabrhelík R, Charvát M. Analýza potřeb klientů nízkoprahových zařízení. Praha: Úřad vlády ČR; 2005.
24. Hair JF Jr., Black WC, Babin BJ, Anderson RE, Tatham RL. Multivariate data analysis (6th Ed.). Upper Saddle River, NJ: Pearson--Prentice Hall, 2006.
25. Mravčík V, Orlíková B. Překryv klientů mezi jednotlivými nízkoprahovými programy a zneužívání buprenorfinu v Praze. Adiktologie, 2007;7(1):13–20.
26. Mravčík V, Orlíková B. Substituční léčba závislosti na opioidech v ČR: kritický pohled. Česká a slovenská psychiatrie, 2019;115(2):577–583.
27. Mravčík V, Strada L, Reimer J, Schulte B. Hepatitis C treatment uptake and adherence among injecting drug users in the Czech Republic. Epidemiologie, mikrobiologie, imunologie, 2014;63(4):265–269.
28. Edland-Gryt M, Skatvedt AH. Thresholds in a low-threshold setting: an empirical study of barriers in a centre for people with drug problems and mental health disorders. Int J Drug Policy, 2013;24(3):257–264.
29. Treloar C, Newland J, Rance J, Hopwood M. Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals. J Viral Hepat., 2010;17(12):839–844.
30. Grebely J, Genoway K, Khara M, Duncan F, Viljoen M, Elliott D, et al. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int J Drug Policy, 2007;18(5):437–443.
31. Teasdale KE, Keren KM, Kiel A, Becker K. Improving services for prevention and treatment of substance misuse for Aboriginal communities in a Sydney Area Health Service. Drug and Alcohol Review, 2008;27(2):152–159.
32. Litwin AH, Soloway I, Gourevitch MN. Integrating Services for Injection Drug Users Infected with Hepatitis C Virus with Methadone Maintenance Treatment: Challenges and Opportunities. Clinical Infectious Diseases, 2005;40(Suppl. 5):S339–345.
33. Edlin BR. Prevention and treatment of hepatitis C in injection drug users. Hepatology, 2002;36(5, Suppl. 1):S210–219.
Labels
Hygiene and epidemiology Medical virology Clinical microbiologyArticle was published in
Epidemiology, Microbiology, Immunology
2020 Issue 2
Most read in this issue
- The significance of p16 protein expression in oral squamous cell carcinoma
- Q fever and prevention
- Neonatal pneumonia caused by Trichomonas vaginalis
- Vzácná invazivní fungální infekce Mucor circinelloides a Fusarium u imunokompetentního pacienta po devastačním poranění dolní končetiny s rekonstrukcí volným lalokem m. latissimus dorsi